<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717739</url>
  </required_header>
  <id_info>
    <org_study_id>13.01.2021</org_study_id>
    <nct_id>NCT04717739</nct_id>
  </id_info>
  <brief_title>TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study</brief_title>
  <official_title>Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional study aims to investigate change over time in cognitive function,&#xD;
      sleep quality, and activity in daily life as important determinants of QoL in a large cohort&#xD;
      of GBM patients in Germany treated with TTFields in routine clinical care using&#xD;
      low-threshold, electronic PRO and modern automated tracking data analyses. The gained results&#xD;
      will allow even better understanding of TTFields therapy in daily life of GBM patients and&#xD;
      consequently, better informing patients about what to expect when starting this therapy,&#xD;
      increasing therapy compliance in the long-term.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma (GBM) is the most common malignant primary tumor of the brain with an annual&#xD;
      incidence of approximately 3/100.000. Since 2005 the treatment for newly diagnosed GBM&#xD;
      consisted of maximal surgical resection, approx. 60 Gy of radiotherapy together with&#xD;
      chemotherapy using temozolomide (TMZ), followed by 6 cycles of maintenance chemotherapy. This&#xD;
      treatment regimen demonstrated increased median overall survival (OS) from 12.1 to 14.6&#xD;
      months in comparison to surgery and radiotherapy alone in 2005.&#xD;
&#xD;
      Since 2005, despite plenty of clinical phase III trials conducted, Tumor Treating Fields&#xD;
      (TTFields) therapy was the first treatment shown to significantly increase median&#xD;
      progression-free survival (PFS), OS and one to five year survival rates compared to the&#xD;
      previous standard of care. These results led to FDA approval of TTFields for newly diagnosed&#xD;
      GBM and were acknowledged since then by several guidelines recommending TTFields for GBM&#xD;
      therapy (e.g. NCCN guidelines for CNS cancers V.1.2018, RCC guideline tumörer I hjärna och&#xD;
      ryggmärg 2020-01-14 V3.0, DGHO guideline for glioma in adults ICD-10 C71 March 2019). Today,&#xD;
      several national committees in Europe already list TTFields as reimbursed treatment (e.g.&#xD;
      Austria, Sweden, Germany).&#xD;
&#xD;
      Data with TTFields therapy in real-world setting is limited and therefore further evaluation&#xD;
      of different treatment aspects of TTFields therapy in clinical routine are of interest. In&#xD;
      particular the QoL-related aspects neurocognitive functioning, daily activity and sleep&#xD;
      quality in this patient cohort is of major interest, given the limited life expectancy with&#xD;
      this disease.&#xD;
&#xD;
      This non-interventional study aims to investigate change over time in neurocognitive&#xD;
      functioning, sleep quality, and activity in daily life as important determinants of QoL in a&#xD;
      large cohort of GBM patients in Germany treated with TTFields in routine clinical care using&#xD;
      low-threshold, electronic PRO and modern automated tracking data analyses. The gained results&#xD;
      will allow even better understanding of TTFields therapy in daily life of GBM patients and&#xD;
      consequently, better informing patients about what to expect when starting this therapy,&#xD;
      increasing therapy compliance even further in the long-term.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time of usage of TTFields treatment in follow-up derived from monitoring data of the devices, standardised to usage days, as measure of compliance with TTFields treatment.</measure>
    <time_frame>through study completion, an average of 18 months (mean follow-up time)</time_frame>
    <description>Time of usage (compliance) of TTFields treatment over time is measured using the treatment compliance report at the Follow-up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of TTFields treatment-related SAEs as assessed by the CEC standardized to one year of FU time</measure>
    <time_frame>through study completion, an average of 18 months (mean follow-up time)</time_frame>
    <description>Number of TTFields treatment-related SAEs standardized to one year of follow-up (FU) is measured using the collection of SAEs during the follow-up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in daily physical activity as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy</measure>
    <time_frame>Up to 4 months after start of TTFields treatment compared to baseline</time_frame>
    <description>Changes in daily physical activity will be assessed by smartphone app-based clinical monitoring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in sleep quality as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy</measure>
    <time_frame>Up to 4 months after start of TTFields treatment compared to baseline</time_frame>
    <description>Changes in sleep quality will be assessed by smartphone app-based clinical monitoring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in neurocognitive functioning as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy.</measure>
    <time_frame>Up to 4 months after start of TTFields treatment compared to baseline</time_frame>
    <description>Changes in neurocognitive functioning will be assessed by means of MoCA interview tests.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>GBM with indication for TTFields</arm_group_label>
    <description>newly diagnosed GBM with clinical indication for TTFields</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TTFields</intervention_name>
    <description>Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.</description>
    <arm_group_label>GBM with indication for TTFields</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with newly diagnosed, histologically confirmed GBM and an indication for treatment&#xD;
        with NovoTTF-200A System (Optune®) according to IFU and medical guidelines will be&#xD;
        enrolled. Patients' written informed consent to use their routine clinical data and&#xD;
        app-based monitoring data according to data privacy standards must be obtained prior to&#xD;
        documentation of patients' data in the e-CRF.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  min.18 years of age&#xD;
&#xD;
          -  Newly diagnosed, histologically confirmed GBM&#xD;
&#xD;
          -  Patient after completion of radiochemotherapy but within first 3 cycles of first-line&#xD;
             tumor-specific maintenance chemotherapy&#xD;
&#xD;
          -  Clinical indication of treatment with NovoTTF-200A System (Optune®) according to IFU&#xD;
             and medical guidelines&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any foreseeable deviation from the IFU of NovoTTF-200A System (Optune®)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Glas, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Essen, Essen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharina Holzner</last_name>
    <phone>0049 89 990 1649 973</phone>
    <email>tigerpro@cri-muc.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Glas, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150.</citation>
    <PMID>31675094</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.</citation>
    <PMID>25163906</PMID>
  </reference>
  <reference>
    <citation>Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.</citation>
    <PMID>24552318</PMID>
  </reference>
  <reference>
    <citation>Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.</citation>
    <PMID>24101040</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.</citation>
    <PMID>26670971</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.</citation>
    <PMID>29260225</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95.</citation>
    <PMID>15126372</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </reference>
  <reference>
    <citation>Gutin PH, Wong ET. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. Am Soc Clin Oncol Educ Book. 2012:126-31. doi: 10.14694/EdBook_AM.2012.32.126.</citation>
    <PMID>24451721</PMID>
  </reference>
  <reference>
    <citation>Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015 May 26;10(5):e0125269. doi: 10.1371/journal.pone.0125269. eCollection 2015.</citation>
    <PMID>26010837</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.</citation>
    <PMID>26658786</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </reference>
  <reference>
    <citation>Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.</citation>
    <PMID>29392280</PMID>
  </reference>
  <reference>
    <citation>Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis. 2017 Apr 20;8(4):e2753. doi: 10.1038/cddis.2017.171.</citation>
    <PMID>28425987</PMID>
  </reference>
  <reference>
    <citation>Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy. Semin Oncol. 2014 Oct;41 Suppl 6:S25-34. doi: 10.1053/j.seminoncol.2014.09.008. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e56-66.</citation>
    <PMID>25213871</PMID>
  </reference>
  <reference>
    <citation>Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019 Jan;141(2):467-473. doi: 10.1007/s11060-018-03057-z. Epub 2018 Dec 1.</citation>
    <PMID>30506499</PMID>
  </reference>
  <reference>
    <citation>Onken J, Goerling U, Heinrich M, Pleissner S, Krex D, Vajkoczy P, Misch M. Patient Reported Outcome (PRO) Among High-Grade Glioma Patients Receiving TTFields Treatment: A Two Center Observational Study. Front Neurol. 2019 Oct 1;10:1026. doi: 10.3389/fneur.2019.01026. eCollection 2019.</citation>
    <PMID>31681134</PMID>
  </reference>
  <reference>
    <citation>Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011 Sep;104(3):639-46. doi: 10.1007/s11060-011-0565-x. Epub 2011 Apr 6. Review.</citation>
    <PMID>21468776</PMID>
  </reference>
  <reference>
    <citation>Bergo E, Lombardi G, Guglieri I, Capovilla E, Pambuku A, Zagone V. Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature. Eur J Cancer Care (Engl). 2019 Jan;28(1):e12410. doi: 10.1111/ecc.12410. Epub 2015 Nov 4. Review.</citation>
    <PMID>26531122</PMID>
  </reference>
  <reference>
    <citation>Coomans MB, Dirven L, Aaronson NK, Baumert BG, Van Den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? Neuro Oncol. 2019 Nov 4;21(11):1447-1457. doi: 10.1093/neuonc/noz118.</citation>
    <PMID>31682733</PMID>
  </reference>
  <reference>
    <citation>Armstrong TS, Shade MY, Breton G, Gilbert MR, Mahajan A, Scheurer ME, Vera E, Berger AM. Sleep-wake disturbance in patients with brain tumors. Neuro Oncol. 2017 Mar 1;19(3):323-335. doi: 10.1093/neuonc/now119. Review.</citation>
    <PMID>27286798</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>GBM</keyword>
  <keyword>Tumor Treating Fields</keyword>
  <keyword>TTFields</keyword>
  <keyword>ePRO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

